MedTrace Logo

A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment

NCT01267526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 205

Last updated 2017-12-26

No results posted yet for this study

Summary

This is a Canadian, Multicentre, Observational Registry to study Adherence and Long Term Outcomes of Therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospital and to assess the level of adherence of subject receiving SAIZEN® via Easypod™ .

Conditions

  • Growth Disorders

Interventions

DEVICE

Easypod™

Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph

Sponsors & Collaborators

  • EMD Serono, a division of EMD Inc., Canada

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · EMD Serono, a division of EMD Inc., Canada

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01267526 on ClinicalTrials.gov